LMAT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
LeMaitre Vascular Inc (LMAT) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company demonstrates strong financial growth, positive analyst sentiment, and bullish technical indicators. Despite hedge fund selling, the stock's fundamentals and growth trajectory make it a solid choice for long-term investment.
The stock is showing bullish momentum with MACD above 0 and positively contracting, RSI at 66.5 in the neutral zone, and bullish moving averages (SMA_5 > SMA_20 > SMA_200). The current price of $106.15 is close to the pivot level of $101.763, with resistance levels at $112.071 and $118.439, indicating potential upside.
Strong financial performance in Q4 2025 with revenue up 15.68% YoY, net income up 39.32% YoY, and EPS up 38.78% YoY.
Analysts have raised price targets and maintained positive ratings, citing impressive sales growth, operating leverage, and international expansion.
Bullish technical indicators support upward price momentum.
Hedge funds are selling, with a significant 398.42% increase in selling over the last quarter.
Lack of recent news or event-driven catalysts.
In Q4 2025, LeMaitre reported revenue of $64.45M (+15.68% YoY), net income of $15.58M (+39.32% YoY), and EPS of $0.68 (+38.78% YoY). Gross margin improved to 71.66%, up 3.47% YoY, indicating strong operational efficiency.
Analysts have raised price targets: Roth Capital to $117, Barrington to $105, and Citizens to $118, all maintaining positive ratings. Analysts highlight double-digit organic growth, margin expansion, and strong cash flow as key drivers.
